No abstract

do well on imatinib 400mg/day with no evidence of ETV6-ABL1 transcript by qRT-PCR for the past five years.Somatic mutations in UTX, ASXL1, and TET2 have been reported in chronic myeloid leukemia and mutations in EZH2 and IDH1/2 in myeloid malignancies other than CML. We found no somatic alterations in these genes in the DNA extracted from whole blood prior to imatinib treatment, nor when the patient was in a molecular remission.Our studies indicate that ETV6-ABL1

We conducted a retrospective population-based study of patients diagnosed with acute myeloid leukemia (AML) in northern England (population 3.1 million) in order to assess the impact of age and genetics on outcome. Four hundred and sixteen patients were diagnosed with AML, between 2007 and 2011. In those aged ≤60 years (n = 20) with acute promyelocytic leukemia (APL) overall survival (OS) was 100%. For non-APL patients aged ≤60 years, OS for those with favorable, intermediate and adverse cytogenetics was not reached, 17 and 9.8 months, respectively (p = 0.0001). Of particular note, intensively treated patients aged >60 years with intermediate cytogenetics and FLT3-/NPM1+ status had a five-year survival of 60% versus median OS of 11 months for other subsets (p = 0.04). Population-based studies reduce selection bias and have utility in studying rarer diseases, particularly in populations that recruit poorly to trials. The highly favorable outcome in our subgroup of intensively-treated FLT3-/NPM1+ older patients merits further study.

No abstract